Cell cultures of the wild sunflower Helianthus maximiliani schrader: growth and secondary metabolite synthesis

Summary Callus cultures derived from leaves, stem, sepals and ray flowers and cell suspension cultures of Helianthus maximiliani Schrader were established and analysed for their phytochemicals. Dark-grown cultures were found to synthesize small amounts of non-toxic, polycyclic diterpenoids when grown on modified MS-medium, while -sitosterol and palmitic acid were found in dark- and light-grown cultures. Red light irradiation did not enhance terpenoid production compared to dark- and light-grown cells.Abbreviations 2,4-D 2,4-Dichlorophenoxyacetic acid - NAA naphthaleneacetic acid - BA N-6-benzyladenine - GA gibberellic acid - TLC thin layer chromatography - GC/MS combined gas chromatography-mass specitroscopy - f wt fresh weight     

Brickellin,a novel flavone from brickellia veronicaefolia and b. chlorolepis

A new highly oxygenated flavone methyl ether has been isolated from Brickellia veronicaefolia and B. chlorolepis. It has been identified as 5,6′-dihydroxy-6,7,2′,3′,4′-pentamethoxyflavone and given the name brickellin.     

Sesquiterpene lactones from Viguiera deltoidea

Three sesquiterpene lactones, 2′,3′-dihydroniveusin-A, 2′,3′-dihydroniveusin-B and 3-acetylchamissonin, were isolated from the dichloromethane extract of leaves of Viguiera deltoidea. The structures were established on the basis of physical and spectroscopic data and that of 3-acetylchamissonin was also confirmed by X-ray analysis.     

S-type sieve-element plastids and anthocyanins inVivianiaceae: Evidence against its inclusion intoCentrospermae

The presence of S-type sieve-element plastids and anthocyanins in theVivianiaceae indicates that it is not a member ofCentrospermae (Caryophyllales).     

A dual-targeting PDGFRβ/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo

Targeting angiogenesis is a promising approach to the treatment of solid tumors and age-related macular degeneration (AMD). Inhibition of vascularization has been validated by the successful marketing of monoclonal antibodies (mAbs) that target specific growth factors or their receptors, but there is considerable room for improvement in existing therapies. Combination of mAbs targeting both the VeGF and pDGF pathways has the potential to increase the efficacy of anti-angiogenic therapy without the accompanying toxicities of tyrosine kinase inhibitors and the inability to combine efficiently with traditional chemotherapeutics. However, development costs and regulatory issues have limited the use of combinatorial approaches for the generation of more efficacious treatments.The concept of mediating disease pathology by targeting two antigens with one therapeutic was proposed over two decades ago. While mAbs are particularly suitable candidates for a dual-targeting approach, engineering bispecificity into one molecule can be difficult due to issues with expression and stability, which play a significant role in manufacturability. Here, we address these issues upstream in the process of developing a bispecific antibody (bsAb). Single-chain antibody fragments (scFvs) targeting pDGFRβ and VeGF-A were selected for superior stability. the scFvs were fused to both termini of human Fc to generate a bispecific, tetravalent molecule. resulting molecule displays potent activity, binds both targets simultaneously, and is stable in serum. assembly of a bsAb using stable monomeric units allowed development of an anti-pDGFRB/VeGF-A antibody capable of attenuating angiogenesis through two distinct pathways and represents an efficient method for rapid engineering of dual-targeting molecules.Key words: bispecific, antibody, PDGFRβ, VEGF-A, stability, angiogenesis